Pharmacia · 2021 · 14 citations · 23 references
Life SciencesGeneticsMolecular GeneticsHuman GeneticsPharmacogeneticsPopulation GeneticsGenotype-phenotype CorrelationMolecular Population GeneticsPopulation PharmacogeneticsAllele FrequencyCyp2d6 GenotypeCyp2d6 GenotypingCyp2d6 PharmacogeneticsCyp2d6 PhenotypingCytochrome P450 Genetic PolymorphismCytochrome P450 GenotypingIntermediate Metabolizer Phenotype
Wild type genotypes ( CYP2D6 ) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4 . The percentages of genotypes described were 97% CYP2D6*1/*1 and 3.0% CYP2D6*1/*3 ; 90.60% for CYP2D6*1/*1 , 8.55% CYP2D6*1/*4 and 0.85% CYP2D6*4/*4 . The allelic frequencies of CYP2D6*3 in the Lima subpopulations were 0.022 and 0.010 for Junin; CYP2D6*4 of 0.048, 0.060, and 0.050 for residents of Lima, Junín, and Tacna, respectively. The Hardy-Weinberg equilibrium test for the studied population showed that both frequencies are in equilibrium, p <.05. The metabolizer phenotype was inferred according to the genotypes: 11.54% were classified as intermediate metabolizers (*1/*3 or *1/*4) and 0.85% as poor metabolizers (*4/*4). It is concluded that the frequencies of the CYP2D6*3 and CYP2D6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental population, due to their natural population evolution, which is manifested by their decreased metabolic activity, the same that is relevant in clinical practice.
23
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Shufeng Zhou · Clinical Pharmacokinetics · 2009 · 759 citations
Medicine, Genetics, Pharmacology +14